Form 4 Intellia Therapeutics, For: Jun 17 Filed by: Verwiel Frank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'
June 24, 2024 12:15 PM EDTStifel analyst Dae Gon Ha reiterated a Buy rating and $80.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach and with the Ph.3 MAGNITUDE study ongoing, should be seen... More
Baird on Intellia Therapeutics (NTLA): 'we anticipate enthusiasm will wane'
June 24, 2024 9:49 AM EDTBaird analyst Jack Allen reiterated a Neutral rating and $24.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "No change to outlook on competitor's clinical data. This morning, Alnylam (ALNY, not covered) announced positive top-line results from the HELIOS-B study of their... More
